Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 220

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 220
---
 of International Supply Chain and Site Head between 2007 and 2011. Ms. Merchant currently serves
on the board of directors of Alvotech S.A. (NASDAQ: ALVO), a biosimilar company. Ms. Merchant holds an MBA from the Henley Business
School and a Bachelor of Science in Languages from Georgetown University.

Compensation of Non-Executive Directors

Our non-executive directors
receive a fee for their services as a director, which is approved by our Board of Directors, giving due consideration to the time commitment
and responsibilities of their roles and of current market rates for comparable organizations and appointments. Non-executive directors
are reimbursed for travelling and other incidental expenses incurred on our business in accordance with our expenses policy.

The following table summarizes
the compensation paid to our non-employee directors during 2024.

| Name            |     | Fees Earned  
 or           
 Paid in Cash 
 (£)(1)       |        |     | Option 
 Awards 
 (£)(2) |         |     | Total 
 (£)   |         |
| Sijmen de Vries |     |              | 40,000 |     |        |  76,085 |     |       | 116,085 |
| Simon Turton    |     |              | 40,000 |     |        |  76,085 |     |       | 116,085 |
| Stephen Parker  |     |              | 82,000 |     |        | 152,170 |     |       | 192,170 |
| Ann Merchant    |     |              | 40,000 |     |        |  76,085 |     |       | 116,085 |

______________

| (1) | Includes annual fees, committee chairpersonship fees and meeting fees. |

| (2) | The amounts shown in this column reflect the grant date fair value                                                                    
 of option awards granted for service during the applicable year and determined without regard to forfeitures. The assumptions used to 
 determine the grant date fair values of awards granted during the fiscal year ended December 31, 2024 will be disclosed in our Annual 
 Report on Form 20-F for the year ending December 31, 2024.                                                                            |

The following table sets forth,
as of December 31, 2024, the aggregate number of option awards, which options are exercisable for Ordinary Shares (issued in the form
of Depositary Shares), held by those individuals who served as